Merck’s stock rallies toward a record after FDA OKs arterial-hypertension drug

Merck’s stock rallied into record territory Wednesday, after the drug giant’s treatment for pulmonary arterial hypertension, Winrevair, was approved by the U.S. Food and Drug Administration.

Previous post Land’s End stock rises as retailer posts stronger-than-expected sales
Next post How has this $25 billion fund beaten the S&P 500? Patience — and preparing for ‘the next big thing’